News | Radiopharmaceuticals and Tracers | July 01, 2019

Transaction set to close in Q3 2019, bringing Axumin novel PET imaging agent into Bracco product portfolio

Bracco Imaging Acquires Blue Earth Diagnostics

July 1, 2019 — Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company based in Oxford, U.K. Subject to customary closing conditions, completion of the transaction is expected in the third quarter of this calendar year.

Bracco Imaging will acquire all outstanding shares of privately-held Blue Earth Diagnostics for the equity value of $450 million, plus closing adjustment estimated at $25 million, from healthcare company Syncona and Blue Earth Diagnostics' management team. Upon closing of the transaction, Blue Earth Diagnostics will be a subsidiary of Bracco Imaging, led by its current leadership team and will retain the Blue Earth Diagnostics name. Blue Earth Diagnostics employs approximately 100 people and is expected to generate revenues of $140 million in the year to September 2019, primarily in the U.S.

The first novel positron emission tomography (PET) molecular imaging agent developed by Blue Earth Diagnostics is Axumin (F18-fluciclovine) injection. Axumin is approved in the U.S. and the European Union for PET imaging in men with suspected recurrent prostate cancer based on elevated prostate specific antigen (PSA) levels following prior treatment. The company's pipeline includes prostate specific membrane antigen (PSMA)-targeted radiohybrid ("rh") agents, which are a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer.

Prostate cancer is the most common cancer in men, with an estimated number of more than 170 thousand new cases in 2019 in the U.S. While most cases of primary prostate cancer can be treated successfully, the cancer will recur in up to one third of cases and in a third of those recurrences, patients develop distant metastases leading to a fatal outcome. In two separate studies which evaluated the utility of Axumin (F18-fluciclovine) PET/CT (computed tomography) in providing physicians with actionable information for the management of men with recurrent prostate cancer, the intended management plan was changed for approximately 60 percent of the study subjects, based on the results of the Axumin PET/CT scan.

F18-fluciclovine has a broad range of other potential applications in cancer imaging and Blue Earth Diagnostics is investigating the molecule for other cancers including in neuro-oncology.

For more information: www.braccoimaging.com, www.blueearthdiagnostics.com


Related Content

News | Artificial Intelligence

November 29, 2023 — The Radiological Society of North America (RSNA) has announced the results of the “RSNA Abdominal ...

Time November 29, 2023
arrow
News | Artificial Intelligence

November 29, 2023 —Flywheel, a leading medical imaging artificial intelligence (AI) development platform, today ...

Time November 29, 2023
arrow
News | Contrast Media

November 29, 2023 — Bayer continues to advance its comprehensive Radiology portfolio with progress in the development ...

Time November 29, 2023
arrow
News | RSNA

November 28, 2023 — Curtis P. Langlotz, MD, PhD, has taken the helm as 2023-2024 president of the Radiological Society ...

Time November 29, 2023
arrow
News | Pediatric Imaging

November 29, 2023 — Using artificial intelligence (AI) to analyze specialized brain MRI scans of adolescents with and ...

Time November 29, 2023
arrow
News | Breast Imaging

November 29, 2023 — A deep learning artificial intelligence (AI) model that was developed using only mammogram image ...

Time November 29, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

November 29, 2023 — Researchers have identified objective evidence of how the neck muscles are involved in primary ...

Time November 29, 2023
arrow
Feature | RSNA | Christine Book

November 29, 2023 — Following the theme of the Radiological Society of North America Scientific Assembly and Annual ...

Time November 29, 2023
arrow
News | Artificial Intelligence

November 28, 2023 — Combining Vista.ai's leading radiology AI-guided software that automates MRI exams for quick and ...

Time November 28, 2023
arrow
News | Artificial Intelligence

November 28, 2023 — iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, and ...

Time November 28, 2023
arrow
Subscribe Now